Dual Mobility Cup Versus Unipolar Cup

Dislocation, Hip Clinical Trial

Official title:

Risk of Dislocation After Total Hip Replacement: Dual Mobility Cup vs. Unipolar Cup. A Randomized Controlled Trial With Patients ≥65 Years Operated for Hip Osteoarthritis With Primary Total Hip Replacement (THR).

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04685239
• Other study ID #: N-20190040
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 1, 2023
• Est. completion date: December 2035

Study information

• Verified date: March 2023
• Source: Northern Orthopaedic Division, Denmark
• Contact: Anders Diernæs, MD
• Phone: +4597662503
• Email: anders.diernaes[@]rn.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The general purpose of this study is to examine whether the dual mobility cup (Novae® Serf) reduces the number of hip dislocations after total hip replacement, both early dislocation (≤1 year) and late dislocation (>1 year) after primary THR compared with a conventional cup design (Trabecular MetalTM Modular Acetabular System).

Description:

Surgery with THR for arthritis and other hip disorders has long been one of the most successful orthopedic surgical treatments. The majority of the patients gain pain relief and experience improved hip function. In 2017, a total of 10,691 THRs were implanted in Denmark (annual report 2018).

Hip dislocation is a known complication after THR. It is a painful condition which may have far-reaching consequences for the patient, who may experience both physical and mental discomfort. Ultimately, multiple hip dislocations may result in reoperation.

In the literature, the incidence of hip dislocation is reported at 2-6 %, and a more recent review reports a risk of 0.5-10 %.

In Denmark, recurrent hip dislocation is the cause of 21 % of the reoperations per year according to The Danish Hip Arthroplasty Register. According to the British National Joint Registry (NJR) and the Australian register (AOANJRR), hip dislocation is the cause of 15.5 % and 21 %, respectively, of the reoperations.

The best method to avoid reoperation due to instability is to choose the correct implant for the individual patient and thereby spare the patient of having to endure a painful complication and yet another procedure. There are multiple risk factors for instability after THR, and increased use of dual mobility cups (DMC) is already documented.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: December 2035
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Patients with hip arthritis who are amenable to surgery with THR and age = 65 years referred to the Department of Orthopedic Surgery at either Section Farsø, Frederikshavn Hospital or Aalborg University Hospital. Patients who are willing to participate in the trial and who give their written, informed consent after receiving oral and written information.

Exclusion Criteria:

• Patients who do not wish to participate.

• Sequelae of Calvé-Legg-Perthes' disease, caput necrosis, epiphysiolysis.

• Proximal femoral or acetabular fracture.

• Hip dysplasia with subluxation Crowe types III and IV.

• Earlier hip bone surgery (excluding arthroscopic surgery).

• Elective bilateral surgery.

• If the patient's bone morphology is unsuitable for a cemented Exeter® femoral stem.

• Patients with no e-mail.

Related Conditions & MeSH terms

• Dislocation, Hip
• Hip Dislocation

Intervention

Device:
• dual mobility cup
The use of a Sunfit dual mobility cup
• unipolar cup
The use of a TMT cup

Locations

Country	Name	City	State
Denmark	Aalborg University Hospital	Aalborg	Northen Denmark

Sponsors (1)

Lead Sponsor	Collaborator
Northern Orthopaedic Division, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Early dislocation, Difference in dislocation within 1 year.	The primary outcome is the difference in cumulative incidence proportion of dislocation between the 2 randomized groups within the first year after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.	1 year after surgery
Secondary	Difference in dislocation within 5 years	The difference in cumulative incidence proportion of dislocation between the 2 randomized groups within 5 years after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.	5 years after surgery
Secondary	Dislocation 10 year	The difference in cumulative incidence proportion of dislocation between the 2 randomized groups within 10 years after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.	10 years after surgery
Secondary	Prosthesis survival.	Evaluated by the cumulative incidence of THR's reoperated within 1, 5 and 10 years after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.	1, 5 and 10 year
Secondary	Patient reported outcome measure: European quality of life 5 dimensions (EQ-5D 5L)	Patients will be scored with EQ-5D 5L preoperatively and at 1,5 and 10 years. It consists of 5 dimensions ranging from 1-5, with 1 being the best in each dimension. It also consist of a visual analog scale ranging from 0-100, 100 being the best imaginable health, The EQ VAS describes the respondents current overall health. Data will be showed as changes in health over time showing responses at baseline and at follow up or as frequencies and proportions reported by dimension and level.	1, 5 and 10 years
Secondary	Patient reported outcome measure: Oxford Hip Score (OHS)	Patients will be scored with OHS at baseline and at 1, 5 and 10 years. OHS is a patient-recorded outcome measure designed to assess the outcome of hip replacements. Its a score between 0-48 with 48 being the best.	1, 5 and 10 years
Secondary	Patient reported outcome measures: The Copenhagen Hip and Groin Outcome Score (HAGOS)	HAGOS pain subscale will be used to report pain pre and postoperatively. The score in the pain subscale ranges from 0 (extreme hip/groin problems) -100 (no hip/groin problems).	1, 5 and 10 years